Business Description
Cingulate Inc. is a Kansas City-based pharmaceutical company focused on developing new treatments for ADHD and anxiety. Its leading drug candidate, CTx-1301, is currently in Phase 3 clinical trials for ADHD patients of all ages, while CTx-2103 is being developed to treat anxiety and CTx-1302 is planned for future clinical testing as an additional ADHD treatment. All three medications are built on the company's proprietary drug delivery technology, which aims to improve how these treatments are administered to patients.
